5 Key Takeaways

• 1

  Biosimilars have emerged as a solution to improve access to anti-VEGF therapy for retinal diseases, addressing cost barriers in healthcare.

• 2

  Anti-VEGF therapy has transformed the management of retinal diseases, shifting the focus from merely slowing visual decline to preserving and improving vision.

• 3

  Biosimilars are not generic drugs; they undergo rigorous evaluation to demonstrate similarity to reference biologics in efficacy, safety, and immunogenicity.

• 4

  Global regulatory agencies have aligned on biosimilar approval processes, emphasizing analytical and functional comparability across regions.

• 5

  Ranibizumab biosimilars are the most widely adopted class, with multiple approvals across various regions, reflecting confidence in their use.